[
Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C, Centanni M, Shoenfeld Y, Ferrari SM. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab 34, 101388, 2020.10.1016/j.beem.2020.10138832059832
]Search in Google Scholar
[
el Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab 92, 1769–1772, 2007.10.1210/jc.2006-238817284622
]Search in Google Scholar
[
el Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130, 252–258, 2009.10.1016/j.clim.2008.09.00718964302
]Search in Google Scholar
[
Hausler D, Hausser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, Zamvil SS, Bruck W, Lehmann-Horn K, Weber MS. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A 115, 9773–9778, 2018.10.1073/pnas.1810470115616680530194232
]Search in Google Scholar
[
Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TWJ, Romijn JA, Smit JW. Rituximab in relapsing Graves’ disease, a phase II study. Eur J Endocrinol 159, 609–615, 2008.10.1530/EJE-08-008418628345
]Search in Google Scholar
[
Kurozumi A, Okada Y, Arao T, Narisawa M, Torimoto K, Yamamoto S, Tanaka Y. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves’ disease and type 1 diabetes mellitus: a case report. Endocr J 62, 69–75, 2015.10.1507/endocrj.EJ14-015225273396
]Search in Google Scholar
[
Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16, 56–62, 2020.10.1038/s41582-019-0268-z31649335
]Search in Google Scholar
[
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376, 209–220, 2017.10.1056/NEJMoa160646828002688
]Search in Google Scholar
[
Muller I, Willis M, Healy S, Nasser T, Loveless S, Butterworth S, Zhang L, Draman MS, Taylor PN, Robertson N, Dayan CM, Ludgate ME. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: Evidence that TRAb may precede thyroid dysfunction by many years. Thyroid 28, 1682–1693, 2018.10.1089/thy.2018.023230351224
]Search in Google Scholar
[
Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, Dayan CM. 2019 European Thyroid Association Guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J 8, 173–185, 2019.
]Search in Google Scholar
[
Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156, 33–40, 2007.10.1530/eje.1.0232517218723
]Search in Google Scholar
[
Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100, 422–431, 2015.10.1210/jc.2014-3014431889925494967
]Search in Google Scholar
[
Sellner J, Rommer PS. Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review. Autoimmun Rev 19, 102492, 2020.10.1016/j.autrev.2020.10249232062028
]Search in Google Scholar
[
Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab 23, 693–702, 2009.10.1016/j.beem.2009.07.00319942146
]Search in Google Scholar
